Dynavax Technologies’ GMP manufacturing facility in Duesseldorf, Germany has been approved for the commercial production of hepatitis B surface antigen, a key component of HEPLISAV, the company’s investigational adult hepatitis B vaccine. The approval comes as a result of an upgrade expanding production capacity. With an updated EU GMP manufacturing license in place, Dynavax can meet the initial commercial production demands for the anticipated launch of HEPLISAV, according to a comp...